GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (OTCPK:BIESF) » Definitions » Cyclically Adjusted Price-to-FCF

Biotest AG (Biotest AG) Cyclically Adjusted Price-to-FCF : 609.60 (As of Jun. 08, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Biotest AG Cyclically Adjusted Price-to-FCF?

As of today (2024-06-08), Biotest AG's current share price is $30.48. Biotest AG's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $0.05. Biotest AG's Cyclically Adjusted Price-to-FCF for today is 609.60.

The historical rank and industry rank for Biotest AG's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

BIESF' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 20.6   Med: 62.3   Max: 4300
Current: 596.95

During the past years, Biotest AG's highest Cyclically Adjusted Price-to-FCF was 4300.00. The lowest was 20.60. And the median was 62.30.

BIESF's Cyclically Adjusted Price-to-FCF is ranked worse than
95.24% of 105 companies
in the Biotechnology industry
Industry Median: 49.53 vs BIESF: 596.95

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Biotest AG's adjusted free cash flow per share data for the three months ended in Mar. 2024 was $-0.316. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.05 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biotest AG Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Biotest AG's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG Cyclically Adjusted Price-to-FCF Chart

Biotest AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.26 75.41 180.07 1,207.54 770.27

Biotest AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,371.90 - - 770.27 611.36

Competitive Comparison of Biotest AG's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Biotest AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotest AG's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biotest AG's Cyclically Adjusted Price-to-FCF falls into.



Biotest AG Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Biotest AG's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=30.48/0.05
=609.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest AG's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Biotest AG's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.316/125.0381*125.0381
=-0.316

Current CPI (Mar. 2024) = 125.0381.

Biotest AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.731 99.543 -0.918
201409 -0.144 99.823 -0.180
201412 0.863 99.543 1.084
201503 0.357 99.717 0.448
201506 0.522 100.417 0.650
201509 0.085 100.417 0.106
201512 0.107 99.717 0.134
201603 0.566 100.017 0.708
201606 0.835 100.717 1.037
201609 -0.074 101.017 -0.092
201612 0.506 101.217 0.625
201703 -0.337 101.417 -0.415
201706 -0.301 102.117 -0.369
201709 0.419 102.717 0.510
201712 1.302 102.617 1.586
201803 -0.973 102.917 -1.182
201806 -0.602 104.017 -0.724
201809 -0.291 104.718 -0.347
201812 0.345 104.217 0.414
201903 -0.298 104.217 -0.358
201906 -0.007 105.718 -0.008
201909 -0.681 106.018 -0.803
201912 -0.047 105.818 -0.056
202003 -0.301 105.718 -0.356
202006 -0.419 106.618 -0.491
202009 -0.411 105.818 -0.486
202012 0.625 105.518 0.741
202103 -0.481 107.518 -0.559
202106 0.084 108.486 0.097
202109 0.488 109.435 0.558
202112 0.824 110.384 0.933
202203 0.584 113.968 0.641
202206 -0.497 115.760 -0.537
202209 -0.479 118.818 -0.504
202212 -0.622 119.345 -0.652
202303 -1.038 122.402 -1.060
202306 -1.007 123.140 -1.023
202309 0.156 124.195 0.157
202312 1.827 123.773 1.846
202403 -0.316 125.038 -0.316

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biotest AG  (OTCPK:BIESF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Biotest AG Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Biotest AG's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotest AG (Biotest AG) Business Description

Industry
Traded in Other Exchanges
Address
Landsteinerstrasse 5, Dreieich, DEU, 63303
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.

Biotest AG (Biotest AG) Headlines

From GuruFocus

Nine Months 2019 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Full Year 2019 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2021 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2021 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2020 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Nine Months 2020 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2022 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2022 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024